Karsten Knudsen Biography and Net Worth

Exec. VP of Novo Nordisk A/S

Karsten Munk Knudsen joined Novo Nordisk in 1999 as a business analyst in NNIT A/S, previously a subsidiary of Novo Nordisk, and has since held finance positions of growing size and complexity throughout the Novo Nordisk value chain. From 2010 to 2014 Mr Knudsen was corporate vice president for Finance & IT at Novo Nordisk Inc. in the US and in 2014 he was appointed senior vice president of Corporate Finance in Novo Nordisk. In February 2018 Mr Knudsen was promoted to executive vice president and chief financial officer. In April 2019 Mr Knudsen assumed further responsibilities as his area was expanded to cover Finance, Legal & Procurement.

Mr. Knudsen serves as chair of the board of NNE A/S, and as member of the board and chair of the audit committee, as well as a member of the equity & capital markets committee of Hempel A/S, both in Denmark.

How old is Karsten Munk Knudsen?: Mr. Knudsen is currently 53 years old. There are 9 older executives and no younger executives at Novo Nordisk A/S. The oldest executive at Novo Nordisk A/S is Mr. Lars Fruergaard Jorgensen, President, CEO & Member of Management Board, who is 58 years old. Learn More on Karsten Munk Knudsen's age.
How do I contact Karsten Munk Knudsen?: The corporate mailing address for Mr. Knudsen and other Novo Nordisk A/S executives is Novo Alle, Bagsvaerd G7, 2880. Novo Nordisk A/S can also be reached via phone at (454) 444-8888 and via email at [email protected]. Learn More on Karsten Munk Knudsen's contact information.
Has Karsten Munk Knudsen been buying or selling shares of Novo Nordisk A/S?: Karsten Munk Knudsen has not been actively trading shares of Novo Nordisk A/S during the past quarter. Learn More on Karsten Munk Knudsen's trading history.
Who are Novo Nordisk A/S's active insiders?: Novo Nordisk A/S's insider roster includes Lars Jørgensen (President), Karsten Knudsen (Exec. VP), and Marcus Schindler (EVP). Learn More on Novo Nordisk A/S's active insiders.

Karsten Munk Knudsen Insider Trading History at Novo Nordisk A/S

Karsten Munk Knudsen Buying and Selling Activity at Novo Nordisk A/S

Novo Nordisk A/S Company Overview

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Today's Range

Now: $123.45

$121.79

$124.25

50 Day Range

MA: $126.04

$117.62

$135.87

2 Week Range

Now: $123.45

$75.56

$138.28

Volume

3,043,212 shs

Average Volume

4,933,779 shs

Market Capitalization

$553.99 billion

P/E Ratio

45.64

Dividend Yield

1.07%

Beta

0.41

Can't believe it's happening again

From Manward Press | Ad

We explain how this event works in full right here.